Bibliography
- Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 2010;49(12):2337-45
- Mcguire JJ, Haile WH. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs. Biochem Pharmacol 2009;77(7):1161-72
- Mant T, Jurcevic S, Szakacs C, Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects. Clin Ther 2008;30(1):131-42
- Castaneda O, Nair MG. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis. J Rheumatol 2006;33(5):862-4
- Castro AC, Dang LC, Soucy F, Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003;13(14):2419-22
- Gawkrodger DJ, Ormerod AD, Shaw L, Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159(5):1051-76
- Takeshita K, Yamasaki T, Nagao K, CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int Immunol 2004;16(7):947-59
- Burian B, Storka A, Marzluf BA, Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients. Peptides 2009;31(4):603-8